PT  - JOURNAL ARTICLE
AU  - Brown, Michaela C.
AU  - Simpson, Keith
AU  - Kerssens, Jan J.
AU  - Mactier, Robert A.
ED  - , 
TI  - Encapsulating Peritoneal Sclerosis in the New Millennium: A National Cohort Study
AID  - 10.2215/CJN.01260209
DP  - 2009 Jul 01
TA  - Clinical Journal of the American Society of Nephrology
PG  - 1222--1229
VI  - 4
IP  - 7
4099  - http://cjasn.asnjournals.org/content/4/7/1222.short
4100  - http://cjasn.asnjournals.org/content/4/7/1222.full
SO  - CLIN J AM SOC NEPHROL2009 Jul 01; 4
AB  - Background and objectives: The study aim was to establish the incidence and characterize all encapsulating peritoneal sclerosis (EPS) cases in patients treated by peritoneal dialysis (PD).Design, setting, participants, & measurements: The patient cohort, which started PD from January 1, 2000, to December 31, 2007, was identified from the Scottish Renal Registry (n = 1238). Possible EPS cases were identified by the ten adult Scottish renal units. Patient records were examined to ensure cases met diagnostic criteria.Results: Forty-six cases were identified; 19 had their first PD exposure after January 1, 2000. The rate was 1.5%, an incidence of 4.9 per 1000 person-years. The incidence increased with PD duration, with rates of 0, 0.6, 2.0, 3.5, 8.1, 8.8 and 5% at <1, 1 to 2, >2 to 3, >3 to 4, >4 to 5, >5 to 6 and >6 yr PD exposure, respectively. The median PD duration of EPS cases was 5.1 yr (interquartile range [IQR] 3.4 to 6.1 yr). At diagnosis, 12 (26%) were on PD and 33 (72%) were diagnosed <2 yr after PD stopped. The cases had a median of 3.3 episodes of peritonitis (range 0 to 20, IQR 1 to 4.5). Thirty (65%) had used 3.86% dextrose dialysate and 45 (98%) had used Extraneal. The mortality was 42% at 1 yr postdiagnosis with a median survival of 149 d (IQR 61 to 408 d).Conclusions: The incidence reported in this study may be used to inform patients of the minimum risk of developing EPS on PD.